BIOCON391.00

Biocon Ltd.

· Pharma & Health
₹ CrorePeersSUNPHARMADRREDDYSYNGENEMANKINDGLENMARKLAURUSLABSALKEMLUPINMcap ₹63,381 Cr
View
In ₹ Crore except Per Share
12 Months Ending
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Adjustments to Reconcile Profit — Non-cash Items
+ Depreciation & Amortisation1,568.81,687.01,956.7
+ Finance Costs974.4897.4990.3
+ Interest Income0.0-108.7-115.4
+ Dividend Income0.0-2.80.0
+ Fair Value (Gains) / Losses-632.241.5-163.2
+ Share-based Payments100.6137.0163.9
+ Unrealised FX (Gain) / Loss-105.4-57.6-39.7
+ Other Non-cash Items594.544.779.9
+ Other — Cash Effects are Investing / Financing-67.4-1,057.3103.6
+ Other Reconciling Items0.0130.0-55.2
Changes in Working Capital
+ Inventories-886.4-0.3-917.8
+ Trade Receivables — Current-2,417.4548.2624.4
+ Other Current Assets-267.9-205.7-647.1
+ Trade Payables — Current2,936.5580.8-191.7
Cash from Operating Activities
Profit Before Tax (per I/S)1,609.41,886.6447.9478.6
+ Total Adjustments (incl. Working Capital)1,798.12,634.21,788.7
Cash from Operations (pre-tax)3,407.54,520.82,236.6
+ Interest Received — Operating-161.30.00.0
+ Income Taxes Paid292.3459.6242.6
Cash from Operating Activities2,953.94,061.21,994.0
Cash from Investing Activities
+ Acq of Fixed Assets (Capex)1,680.52,136.61,797.9
+ Acq of Intangible Assets251.1206.7113.8
+ Disp of Fixed Assets23.30.00.0
+ Disp of Investment Property0.00.30.0
+ Sale of Investments (Equity / Debt)0.01,825.20.0
+ Acq of Subsidiaries / Businesses (net)553.20.00.0
+ Dividends Received — Investing0.02.80.0
+ Interest Received — Investing144.6114.4148.0
+ Other Inflows / (Outflows) — Investing1,312.4166.5-318.4
Cash from Investing Activities-1,004.5-234.1-2,082.1
Cash from Financing Activities
+ Proceeds from Issue of Shares0.00.58,531.1
+ Proceeds from Exercise of Stock Options30.79.970.4
+ Payments — Change in Ownership of Subsidiaries0.00.05,800.2
+ Proceeds from Debentures / Notes / Bonds800.00.00.0
+ Proceeds from Borrowings696.610,342.8301.3
+ Repayment of Borrowings2,767.89,769.92,707.9
+ Payment of Lease Liabilities41.8138.890.9
+ Interest Paid847.4634.2865.4
+ Dividends Paid203.082.990.8
+ Other Inflows / (Outflows) — Financing0.0-1,581.4-271.2
Cash from Financing Activities-2,332.7-1,854.0-923.6
Net Changes in Cash (pre-FX)-383.31,973.1-1,011.7
+ Effect of FX Rate Changes on Cash2.931.2199.4
Net Changes in Cash-380.42,004.3-812.3
Closing Cash919.52,923.82,111.5
Reference Items
EBITDA3,298.73,166.33,455.33,536.4
EBITDA Margin %22.3620.7520.4120.42
Free Cash Flow (CFO − Capex)1,022.31,717.982.382.3
Free Cash Flow to Equity3,109.6-3,713.9
Free Cash Flow per Basic Share6.3110.600.510.51
Price to Free Cash Flow770.12
Cash Flow to Net Income2.282.845.41
Cash Paid for Taxes292.3459.6242.6
Cash Paid for Interest847.4634.2865.4
As filed, sign as filed: a payment tagged as a positive magnitude in the filing stays positive here, so read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown — depth follows the filer, so a thin statement means a thin filing. Total Adjustments is the filer's own grand total of the reconciliation and spans BOTH the non-cash items and the working-capital block; Profit Before Tax plus it equals Cash from Operations (pre-tax). It can be reported when its components are not, so it is never a sum of the rows above it. No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.